Evaluation of in-house genotyping assay performance using dried blood spot specimens in the global world health organization laboratory network

the WHO DBS Genotyping Working Group

    Research output: Contribution to journalArticlepeer-review

    25 Citations (Scopus)

    Abstract

    In resource-limited settings, there is increased demand for human immunodeficiency virus type 1 drug resistance testing. Because preservation of plasma specimens is often not feasible in resource-limited settings, use of dried blood spots (DBSs) is being adopted. We used 2 panels of DBSs for genotyping assay validation and proficiency testing in selected laboratories in the World Health Organization laboratory network in 14 countries. An amplification sensitivity of 1000 copies/mL was achieved by 2 laboratories. Reproducibility and accuracy of nucleotide sequence determination and resistance-associated mutation identification from DBSs was similar to that previously determined for plasma. International shipping at ambient temperature had no significant effect on amplification success. These studies indicate that DBS-based genotyping is equally reproducible and reliable, although slightly less sensitive, compared with plasma.

    Original languageEnglish
    Pages (from-to)S273-S279
    JournalClinical Infectious Diseases
    Volume54
    Issue numberSUPPL. 4
    DOIs
    Publication statusPublished - 15 May 2012

    Bibliographical note

    Funding Information:
    Financial support. This work was supported by The Bill & Melinda Gates Foundation (to the WHO) and the National Institutes of Health, National Institute of Allergy and Infectious Disease, Division of AIDS (NO1-AI-5004 to the Virology Quality Assurance program. Grant no. NIAID K23 AI074423-05 to MRJ).

    Fingerprint

    Dive into the research topics of 'Evaluation of in-house genotyping assay performance using dried blood spot specimens in the global world health organization laboratory network'. Together they form a unique fingerprint.

    Cite this